bevacizumab + acetazolamide

This combination therapy consists of intravitreal bevacizumab and oral acetazolamide, investigated for the treatment of macular edema secondary to retinal vein occlusion (RVO). Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), thereby reducing vascular permeability and inhibiting angiogenesis. Acetazolamide is a small molecule carbonic anhydrase inhibitor that is thought to promote the resorption of subretinal and intraretinal fluid by affecting ion transport mechanisms in the retinal pigment epithelium. A randomized clinical trial (NCT05290948) conducted by Shahid Beheshti University of Medical Sciences at Torfe Eye Hospital compared this combination against bevacizumab monotherapy, finding that the addition of oral acetazolamide did not provide significant additional short-term functional or anatomical benefits.

Other names

intravitreal bevacizumab and oral acetazolamideIVB + OAintravitreal injection of bevacizumab with acetazolamide tablets